Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Multiple Myeloma 29Leukemia, Myeloid, Acute 14Recurrence 13Hodgkin Disease 12Lymphoma 11Neoplasms 10Breast Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Cutaneous 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Waldenstrom Macroglobulinemia 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Diffuse Intrinsic Pontine Glioma 4Advanced Solid Tumors 4Primary Myelofibrosis 3

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Lomustine 25Cisplatin 25Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Panobinostat × Clear all
NCT01324635 2025-05-02

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Thomas Jefferson University

Phase 1 Terminated
17 enrolled
CNS

Brain Neoplasms, Glioma, Meningioma

NCT04897880 2025-02-24

NORTH

Australian & New Zealand Children's Haematology/Oncology Group

Phase 2 Terminated
25 enrolled
CNS

Brain Neoplasms, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡